[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335959-105":59,"doc-detail-335959-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","p90rsk-pathway-inhibition-synergizes-with-cisplatin-in-tmem16a-overexpressing-head-and-neck-cancer","p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer","","Head and neck squamous cell carcinoma (HNSCC) is a prevalent cancer that frequently metastasizes to lymph nodes. Cisplatin is widely used, relying on DNA repair inhibition and apoptosis, yet resistance and toxicity limit long-term benefit. This study identifies p90RSK, an ERK1/2 downstream target, as a key mediator of cisplatin resistance and demonstrates that combining the p90RSK inhibitor BI-D1870 with cisplatin is a novel strategy to overcome resistance. TMEM16A expression is proposed as an upstream regulator via the ERK pathway and a predictive biomarker for p90RSK-targeted therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/p90rsk-pathway-inhibition-synergizes-with-cisplatin-in-tmem16a-overexpressing-head-and-neck-cancer/335959/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/p90rsk-pathway-inhibition-synergizes-with-cisplatin-in-tmem16a-overexpressing-head-and-neck-cancer/335959.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in HNSCC treatment?","Question",{"text":112,"@type":113},"The study addresses cisplatin resistance and the limitations of platinum chemotherapy, including toxicity and reduced efficacy over time.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which signaling molecule is identified as a mediator of cisplatin resistance?",{"text":117,"@type":113},"p90RSK, described as an ERK1/2 downstream target, is identified as a key mediator of acquired cisplatin resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What combination therapy is proposed to overcome cisplatin resistance?",{"text":121,"@type":113},"The study supports combining the p90RSK inhibitor BI-D1870 with cisplatin as a novel therapeutic strategy to overcome resistance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335959,1790177897,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Yassin-Kassab et al. BMC Cancer (2024) 24:233 [https://doi.org/10.1186/s12885-024-11892-9](https://doi.org/10.1186/s12885-024-11892-9)  \nBMC Cancer  \nRESEARCH Open Access  \np90RSK pathway inhibition synergizes with cisplatin inTMEM16A overexpressing head and neck cancer  \nAbdulkader Yassin-Kassab 1,2†, Suman Chatterjee 1,2†, Nayel Khan 1, Nathaniel Wang 1,2, Vlad C. Sandulache3, Eric H-B. Huang2,4, Timothy F. Burns2,4 and Umamaheswar Duvvuri 1,2,5,6*  \nAbstract  \nHead and neck squamous cell carcinoma (HNSCC) constitutes one of the most common types of human cancersand often metastasizes to lymph nodes. Platinum-based chemotherapeutic drugs are commonly used for treatment of a wide range of cancers, including HNSCC. Its mode of action relies on its ability to impede DNA repair mechanisms, inducing apoptosis in cancer cells. However, due to acquired resistance and toxic side-effects, researchers have been focusing on developing novel combinational therapeutic strategies to overcome cisplatin resistance. In the current study, we identified p90RSK, an ERK1/2 downstream target, as a key mediator and atargetable signaling node against cisplatin resistance. Our results strongly support the role of p90RSK in cisplatin resistance and identify the combination of p90RSK inhibitor, BI-D1870, with cisplatin as a novel therapeutic strategy to overcome cisplatin resistance. In addition, we have identified TMEM16A expression as a potential upstream regulator of p90RSK through the ERK pathway and a biomarker of response to p90RSK targeted therapy in the context of cisplatin resistance.  \nKeywords p90RSK, TMEM16A, Cisplatin, Resistance, BI-1870  \n†Abdulkader Yassin-Kassab and Suman Chatterjee contributed equally to this work.  \n*Correspondence:  \nUmamaheswar Duvvuri  \n[umamaheswar.duvvuri@nyulangone.org](umamaheswar.duvvuri@nyulangone.org)  \n1Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA  \n2UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA  \n3Department of Otolaryngology Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA  \n4Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA  \n5Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA 6Smilow Research Center, 530 First Avenue, 801 . b, New York, NY 10016, USA  \nIntroduction  \nHead and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide in 2022, accounting for 3% of all cancers and just over 1.5% of all cancer deaths in the United States [1]. Despite the recent advancement in our understanding of the disease leading to the development of novel therapeutic strategies, HNSCC related morbidity is still considered severe with a 5-year survival rate of 50% for the last three decades [2]. Current clinical strategies targeting HNSCC rely heavily on surgery, radiotherapy, chemotherapy, and molecularly targeted agents. Since its FDA approval in 1978, cisplatin has been widely used against a range of cancers, including HNSCC, and considered the standard first line treatment [3, 4]. Despite the significant efficacy of this treatment regime, high acute toxicity, increased treatment cost, and  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to o","cbCain6Req4j4t9Y","https://ap.wps.com/l/cbCain6Req4j4t9Y","pdf",5720898,12,"English","# Abstract\n# Introduction\n## Cisplatin use and limitations in HNSCC\n## ERK/p90RSK signaling and therapeutic rationale\n## TMEM16A and biomarker potential","[{\"question\":\"What problem does the study address in HNSCC treatment?\",\"answer\":\"The study addresses cisplatin resistance and the limitations of platinum chemotherapy, including toxicity and reduced efficacy over time.\"},{\"question\":\"Which signaling molecule is identified as a mediator of cisplatin resistance?\",\"answer\":\"p90RSK, described as an ERK1/2 downstream target, is identified as a key mediator of acquired cisplatin resistance.\"},{\"question\":\"What combination therapy is proposed to overcome cisplatin resistance?\",\"answer\":\"The study supports combining the p90RSK inhibitor BI-D1870 with cisplatin as a novel therapeutic strategy to overcome resistance.\"}]","p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer | PDF",1790012956]